Navigation Links
Multiple sclerosis research charges ahead with new mouse model of disease
Date:11/5/2008

November 6, 2008, Cambridge, UK A new study highlights the role of a charge-switching enzyme in nervous system deficits characteristic of multiple sclerosis and other related neurological illness.

Multiple sclerosis (MS) is one of several diseases in which myelin the insulator for electrical signaling in the nervous system breaks down and causes severe deficits in brain and nerve function. Much like the rubber insulation on an electrical cord, myelin surrounds long projections from the body of a neuron, and allows signals to travel down the cell with speed and efficiency. Patients with MS and other "de-myelinating" diseases therefore suffer deficits in balance, coordination, and movement, as well as sensory disturbances, from the loss of this neuronal insulation.

A major research initiative in treating these diseases is identifying the molecular factors and changes that lead to myelin breakdown. In a new study published in Disease Models & Mechanisms (DMM), dmm.biologists.org, a team of Canadian researchers report on a new mouse model of disease which will help in understanding how demyelination occurs. Previous research had identified that an enzyme known as peptidylarginine deiminase 2, or PAD2, is increased in patients with MS, and that PAD2 switches a charge on a protein key to myelin stability. Therefore, Abdiwahab A. Musse and colleagues at the University of Guelph and the Hospital for Sick Children in Ontario created a genetically modified mouse expressing too much of an enzyme known as PAD2. They found that these mice had significant loss of myelin, and also have behavioral deficits, such as abnormal movement, balance, and coordination.

Not only does this work present a new mouse model to study demyleinating disease, but it also stresses the importance of PAD in maintaining myelin integrity. Their work highlights PAD as a potential therapeutic target, as well as a potential marker for early detection of MS and other diseases characterized by a loss of myelin.


'/>"/>

Contact: Donna Perry
donna@biologists.com
44-012-234-33319
The Company of Biologists
Source:Eurekalert

Related biology news :

1. Response to immune protein determines pathology of multiple sclerosis
2. Multiple disease-related research gets green light from the NIH
3. Project aims to reduce complications, multiple surgeries with biodegradable implantable devices
4. Multiple Sclerosis: new MRI contrast medium enables early diagnosis in animal model
5. Fast AFM probes measure multiple properties of biomolecules or materials simultaneously
6. Potential new target for multiple sclerosis therapy
7. Multiple resource management is focus of new technical report
8. Multiple species of bacteria may cause trachoma: Implications for treatment
9. The power of multiples: Connecting wind farms can make a more reliable - and cheaper - power source
10. New magnetic separation technique might detect multiple pathogens at once
11. Israeli scientists identify: Genes that affect responses of multiple sclerosis patients to copaxone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/17/2016)... Global Market Watch: Primarily supported by ownership types; ... Academics) market is to witness a value of US$37.1 billion ... Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen from ... 2014-2020. North America is not way ... Europe at 9.56% respectively. Report Focus: ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
(Date:11/14/2016)... SANTA CLARA, Calif. , Nov. 14, ... of the biometric identification market, Frost & ... Global Frost & Sullivan Award for Visionary ... leading player in the biometric identification market ... a multi-modal verification solution for instant, seamless, ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... ... 01, 2016 , ... DrugDev believes the only way to achieve ... experience. All three tenets were on display at the 2nd Annual DrugDev User Summit ... sponsor, CRO and site organizations to discuss innovation and the future of clinical research. ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Robots will storm ... on December 3rd, 2016. The event, which is held on the United Nations ... helping Americans with Disabilities back into the workplace. Suitable Technologies is partnering with NTI ...
(Date:12/2/2016)... RICHMOND, BC , Dec. 2, 2016 /PRNewswire/ - bioLytical Laboratories, a world leader ... Test, to Kenya,s Pharmaceutical Association members. (Photo: ... ... , , ... Initiative (CHAI) and the Kenya Pharmaceutical Association (KPA) to introduce the INSTI HIV Self ...
(Date:11/30/2016)... York , November 30, 2016 ... as a few players hold a dominant share in ... Charles River Laboratories International, Inc., and Merck KGaA, held ... in 2015. Transparency Market Research observes that these companies ... focused on development products that are do not require ...
Breaking Biology Technology: